201 related articles for article (PubMed ID: 34706703)
1. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
Sajjadi E; Venetis K; Piciotti R; Gambini D; Blundo C; Runza L; Ferrero S; Guerini-Rocco E; Fusco N
BMC Cancer; 2021 Oct; 21(1):1152. PubMed ID: 34706703
[TBL] [Abstract][Full Text] [Related]
2. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
4. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
[TBL] [Abstract][Full Text] [Related]
5. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.
Im SA; Lee KE; Nam E; Kim DY; Lee JH; Han HS; Seoh JY; Park HY; Cho MS; Han WS; Lee SN
Tumori; 2005; 91(6):513-21. PubMed ID: 16457151
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
7. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
9. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
10. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen.
Milovanovic Z; Dzodic R; Susnjar S; Plesinac-Karapandzic V; Juranic Z; Tatic S
J BUON; 2011; 16(1):46-51. PubMed ID: 21674849
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
12. PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tekesin K; Emin Gunes M; Bayrak S; Akar E; Ozturk T; Altinay S; Tural D
J BUON; 2019; 24(5):1920-1926. PubMed ID: 31786856
[TBL] [Abstract][Full Text] [Related]
13. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
Guo W; Wang W; Zhu Y; Zhu X; Shi Z; Wang Y
Int J Clin Exp Pathol; 2015; 8(7):8008-17. PubMed ID: 26339367
[TBL] [Abstract][Full Text] [Related]
15. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Esserman LJ; Moore DH; Tsing PJ; Chu PW; Yau C; Ozanne E; Chung RE; Tandon VJ; Park JW; Baehner FL; Kreps S; Tutt AN; Gillett CE; Benz CC
Breast Cancer Res Treat; 2011 Sep; 129(2):607-16. PubMed ID: 21597921
[TBL] [Abstract][Full Text] [Related]
16. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
17. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
[TBL] [Abstract][Full Text] [Related]
18. PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.
Lopez G; Noale M; Corti C; Gaudioso G; Sajjadi E; Venetis K; Gambini D; Runza L; Costanza J; Pesenti C; Grossi F; Maggi S; Ferrero S; Bosari S; Fusco N
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098071
[TBL] [Abstract][Full Text] [Related]
19. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
